2020—2022年安徽省胸科医院抗结核药物使用情况分析

Application of anti-tuberculosis drugs in Anhui Chest Hospital from 2020 to 2022

目的统计2020—2022年安徽省胸科医院抗结核药物使用情况并分析其变化趋势,为规范其合理应用提供一定参考。方法对2020年1月—2022年12月安徽省胸科医院抗结核药物销售金额、用药频度(DDDs)、日均费用(DDC)以及金额排序/DDDs排序比(B/A)等进行统计分析。结果2020—2022医院抗结核药物销售金额总体呈增长趋势,新型类抗结核药物销售金额2022年较2020年增幅333.43%,注射类降幅72.68%,贝达喹啉、注射用利奈唑胺、环丝氨酸、氯法齐明排名靠前,其中贝达喹啉连续2年销售金额排名第1位。DDDs每年总体基本稳定,排名靠前的为一线口服类抗结核药物:异烟肼、乙胺丁醇、吡嗪酰胺、利福平,2022年DDDs贝达喹啉排名第1位。利奈唑胺等40.00%抗结核药物DDC降低。每年一线口服类抗结核药物B/A均大于1,2022年B/A>0.9的药物占比达60.00%。结论安徽省胸科医院抗结核药物使用基本合理,仍然需要加强监督管理,减小耐药结核发生率。

Objective To investigate anti-tuberculosis drugs usage in Anhui Chest Hospital from 2020 to 2022 and analyze its change trend,so as to provide reference for regulating its rational application.Methods Annual consumption sums,DDDs,DDC,and the B/A of anti-tuberculosis drugs in Anhui Chest Hospital from January 2020 to December 2022 were analyzed statistically.Results From 2020 to 2022,consumption sums of anti-tuberculosis drugs in the hospital showed an overall increasing trend,and consumption sums of new anti-tuberculosis drugs increased by 333.43%in 2022 compared with 2020,while consumption sums of injection drugs decreased by 72.68%.Bedaquiline,linezolid for injection,cycloserine,and clofazimine ranked top,among which bedaquiline ranked first for two consecutive years.DDDs were basically stable every year,and the top ones were first-line oral anti-tuberculosis drugs,such as isoniazid,ethambutol,pyrazinamide,and rifampicin.In 2022,bedaquiline ranked first.DDC of 40.00%anti-tuberculosis drugs such as linezolid decreased.The B/A of first-line oral anti-tuberculosis drugs was greater than 1.In 2022,drugs with B/A>0.9 accounted for 60.00%.Conclusion The use of anti-tuberculosis drugs in Anhui Chest Hospital was basically reasonable,and supervision and management should be strengthened to reduce the incidence of anti-tuberculosis drugs.